NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $2.30 -0.06 (-2.54%) Closing price 04:00 PM EasternExtended Trading$2.36 +0.06 (+2.39%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Connect Biopharma Stock (NASDAQ:CNTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$2.25▼$2.3850-Day Range$1.97▼$2.6652-Week Range$1.23▼$3.82Volume427,874 shsAverage Volume374,792 shsMarket Capitalization$144.83 millionP/E RatioN/ADividend YieldN/APrice Target$7.43Consensus RatingModerate Buy Company Overview Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases. The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis. A second clinical-stage program, CBP-701, selectively inhibits signaling through tumor necrosis factor receptor 1 (TNFR1), a strategy designed to preserve beneficial TNFR2 activity while reducing the risk of systemic immunosuppression. Together, these candidates reflect Connect Biopharma’s commitment to developing differentiated therapies with potentially improved safety and efficacy profiles. Since its founding in 2015, Connect Biopharma has advanced its pipeline through early-phase clinical trials and established strategic partnerships to support long-term development goals. The company completed its initial public offering on the Nasdaq Global Market under the ticker CNTB in 2021, raising capital to fund ongoing studies and expand its research capabilities. Its clinical programs are being evaluated across multiple geographies, including North America and the Asia-Pacific region. Connect Biopharma is led by an executive team and board of directors with extensive experience in biotechnology, pharmaceutical development and commercialization. Leveraging a blend of scientific rigor and clinical expertise, the management group aims to bring novel immunology treatments to patients with high unmet medical need.AI Generated. May Contain Errors. Read More Connect Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 80% of companies evaluated by MarketBeat, and ranked 108th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingConnect Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialConnect Biopharma has a consensus price target of $7.43, representing about 223.0% upside from its current price of $2.30.Amount of Analyst CoverageConnect Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Connect Biopharma are expected to grow in the coming year, from ($1.10) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Connect Biopharma is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Connect Biopharma is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Connect Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.23% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 8.02.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 0.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. News and Social Media1.6 / 5News SentimentN/A News SentimentConnect Biopharma has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.Search Interest2 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $372,000.00 in company stock, which represents 0.2568% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $372,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTB Stock News HeadlinesHC Wainwright Predicts Lower Earnings for Connect BiopharmaAugust 17, 2026 | americanbankingnews.comConnect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to "Hold" RatingAugust 15, 2026 | americanbankingnews.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.August 24 at 1:00 AM | Golden Portfolio (Ad)Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 13, 2026 | americanbankingnews.comConnect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12, 2026 | finance.yahoo.comConnect Biopharma: Attempting To Differentiate Rademikibart From DupixentJuly 23, 2026 | seekingalpha.comConnect Biopharma Holdings (CNTB) Receives a New Rating from OppenheimerJuly 10, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Alkermes (ALKS) and Connect Biopharma Holdings (CNTB)June 19, 2026 | theglobeandmail.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $2.82 on January 1st, 2026. Since then, CNTB shares have decreased by 18.4% and is now trading at $2.30. How were Connect Biopharma's earnings last quarter? Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04. The company earned $2.75 million during the quarter, compared to the consensus estimate of $0.74 million. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $180 million in an initial public offering on Friday, March 19th 2021. The company issued 11,250,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC acted as the underwriters for the IPO. How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and Company Calendar Last Earnings8/12/2026Today8/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CNTB's financial health is in the Green zone, according to TradeSmith. CNTB has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CNTB CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees110Year Founded2012Price Target and Rating Average Price Target for Connect Biopharma$7.43 High Price Target$10.00 Low Price Target$4.00 Potential Upside/Downside+223.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.48 million Net MarginsN/A Pretax Margin-2,329.67% Return on Equity-165.41% Return on Assets-121.58% Debt Debt-to-Equity Ratio0.01 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$2.95 million Price / Sales49.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book3.07Miscellaneous Outstanding Shares62,974,000Free Float48,742,000Market Cap$144.84 million OptionableOptionable Beta-0.23 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CNTB) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersIn 2022, every resident of this state received $3,284Since 1982, Alaska has paid every resident an annual check from its oil wealth, $3,284 in 2022 alone, funded e...Freedom Financial | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
